1,5-Diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists

Iain Robert Greig (Inventor), Ruth Alexandra Ross (Inventor)

Research output: Patent

Abstract

The present invention pertains to cannabinoid (CB) receptor and cannabinoid-like receptor neutral antagonists, and especially CB1 neutral antagonists of Formula (I). The present invention also pertains to these compounds for use in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of the cannabinoid type 1 (CB1) receptor or a non-CB1/non-CB2 cannabinoid-like receptor, for example: an eating disorder; obesity; cardiovascular disease; a disease or disorder characterised by an addiction component; addiction; withdrawal; smoking addiction; smoking withdrawal; drug addiction; drug withdrawal; smoking cessation therapy; a bone disease or disorder; osteoporosis, Paget' s disease of bone; bone related cancer; breast cancer; breast cancer metastases; breast cancer which has metastasised to bone; cancer associated with activation or inactivation of a non-CB1/non-CB2 cannabinoid-like receptor,
Original languageEnglish
Patent numberWO2010020762
IPCWO2010020762
Publication statusPublished - 25 Feb 2010

Fingerprint

Pyrazoles
Cannabinoid Receptor Antagonists
Cannabinoid Receptors
Breast Neoplasms
Smoking
Osteitis Deformans
Bone Neoplasms
Bone Diseases
Smoking Cessation
Osteoporosis
Substance-Related Disorders
Cardiovascular Diseases
Obesity
Neoplasm Metastasis
Bone and Bones
Pharmaceutical Preparations
Neoplasms

Cite this

Greig, I. R., & Ross, R. A. (2010). IPC No. WO2010020762. 1,5-Diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists. (Patent No. WO2010020762).

1,5-Diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists. / Greig, Iain Robert (Inventor); Ross, Ruth Alexandra (Inventor).

IPC No.: WO2010020762. Patent No.: WO2010020762.

Research output: Patent

Greig, IR & Ross, RA 2010, 1,5-Diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists, Patent No. WO2010020762, IPC No. WO2010020762.
Greig, Iain Robert (Inventor) ; Ross, Ruth Alexandra (Inventor). / 1,5-Diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists. IPC No.: WO2010020762. Patent No.: WO2010020762.
@misc{908883094e32495bb49ccca987a0ffb6,
title = "1,5-Diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists",
abstract = "The present invention pertains to cannabinoid (CB) receptor and cannabinoid-like receptor neutral antagonists, and especially CB1 neutral antagonists of Formula (I). The present invention also pertains to these compounds for use in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of the cannabinoid type 1 (CB1) receptor or a non-CB1/non-CB2 cannabinoid-like receptor, for example: an eating disorder; obesity; cardiovascular disease; a disease or disorder characterised by an addiction component; addiction; withdrawal; smoking addiction; smoking withdrawal; drug addiction; drug withdrawal; smoking cessation therapy; a bone disease or disorder; osteoporosis, Paget' s disease of bone; bone related cancer; breast cancer; breast cancer metastases; breast cancer which has metastasised to bone; cancer associated with activation or inactivation of a non-CB1/non-CB2 cannabinoid-like receptor,",
author = "Greig, {Iain Robert} and Ross, {Ruth Alexandra}",
year = "2010",
month = "2",
day = "25",
language = "English",
type = "Patent",
note = "WO2010020762; WO2010020762",

}

TY - PAT

T1 - 1,5-Diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists

AU - Greig, Iain Robert

AU - Ross, Ruth Alexandra

PY - 2010/2/25

Y1 - 2010/2/25

N2 - The present invention pertains to cannabinoid (CB) receptor and cannabinoid-like receptor neutral antagonists, and especially CB1 neutral antagonists of Formula (I). The present invention also pertains to these compounds for use in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of the cannabinoid type 1 (CB1) receptor or a non-CB1/non-CB2 cannabinoid-like receptor, for example: an eating disorder; obesity; cardiovascular disease; a disease or disorder characterised by an addiction component; addiction; withdrawal; smoking addiction; smoking withdrawal; drug addiction; drug withdrawal; smoking cessation therapy; a bone disease or disorder; osteoporosis, Paget' s disease of bone; bone related cancer; breast cancer; breast cancer metastases; breast cancer which has metastasised to bone; cancer associated with activation or inactivation of a non-CB1/non-CB2 cannabinoid-like receptor,

AB - The present invention pertains to cannabinoid (CB) receptor and cannabinoid-like receptor neutral antagonists, and especially CB1 neutral antagonists of Formula (I). The present invention also pertains to these compounds for use in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of the cannabinoid type 1 (CB1) receptor or a non-CB1/non-CB2 cannabinoid-like receptor, for example: an eating disorder; obesity; cardiovascular disease; a disease or disorder characterised by an addiction component; addiction; withdrawal; smoking addiction; smoking withdrawal; drug addiction; drug withdrawal; smoking cessation therapy; a bone disease or disorder; osteoporosis, Paget' s disease of bone; bone related cancer; breast cancer; breast cancer metastases; breast cancer which has metastasised to bone; cancer associated with activation or inactivation of a non-CB1/non-CB2 cannabinoid-like receptor,

M3 - Patent

M1 - WO2010020762

ER -